Advanced Melanoma Global Market Report 2025

Advanced melanoma is a type of melanoma skin cancer that has spread from its original location to other areas of the body. It includes stage III, where the cancer has reached nearby lymph nodes, and stage IV, where it has metastasized to distant organs. Treating advanced melanoma is more complex and often requires a combination of therapies, such as immunotherapy, targeted therapy, chemotherapy, or radiation.

The primary treatment approaches for advanced melanoma include chemotherapy, biological therapy, targeted therapy, and immunotherapy. Chemotherapy involves the use of drugs to eliminate or inhibit the growth of rapidly dividing cancer cells. The various distribution channels for these treatments include hospital pharmacies, online pharmacies, and retail pharmacies. Additionally, multiple end-users benefit from these therapies, including hospitals, cancer research centers, academic institutions, diagnostic centers, ambulatory surgical centers, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The advanced melanoma market research report is one of a series of new reports from The Business Research Company that provides advanced melanoma market statistics, including advanced melanoma industry global market size, regional shares, competitors with an advanced melanoma market share, detailed advanced melanoma market segments, market trends and opportunities, and any further data you may need to thrive in the advanced melanoma industry. This advanced melanoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The advanced melanoma market size has grown strongly in recent years. It will grow from $3.77 billion in 2024 to $4.12 billion in 2025 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to approval of dacarbazine, development of interferon therapy, introduction of ipilimumab, adoption of radiation therapy, emergence of combination therapies, approval of nivolumab and launch of pembrolizumab.

The advanced melanoma market size is expected to see strong growth in the next few years. It will grow to $5.85 billion in 2029 at a compound annual growth rate (CAGR) of 9.2%. The growth in the forecast period can be attributed to development of novel checkpoint inhibitors, rise in personalized medicine, progress in adoptive cell therapy, increasing use of combination therapies, emergence of bispecific antibodies, expansion of oncolytic virotherapy and growing focus on early detection tools. Major trends in the forecast period include AI-powered diagnostic tools, mRNA-based cancer vaccines, crispr-based gene editing, oncolytic virus engineering, liquid biopsy technologies, wearable health monitoring devices, advanced imaging techniques, 3d bioprinting for research, tumor microenvironment modeling and nanotechnology-driven drug delivery systems.

The forecast of 9.2% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. dermatologic oncology by inflating prices of immune checkpoint inhibitors (e.g., pembrolizumab) and BRAF/MEK inhibitor combinations developed in Switzerland and Germany, resulting in delayed therapy initiation and higher immunotherapy costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising incidence of severe sunburns is expected to drive the expansion of the advanced melanoma market. Severe sunburns occur due to excessive exposure to ultraviolet (UV) radiation, leading to redness, pain, swelling, and sometimes blistering. The increasing frequency of severe sunburn cases is attributed to prolonged UV exposure, inadequate sun protection, increased outdoor activities during peak UV hours, and rising global temperatures due to climate change. Repeated or childhood sunburns cause DNA damage in skin cells, potentially leading to genetic mutations that trigger melanoma. For example, in May 2024, Melanoma Focus, a UK-based charity supporting the melanoma community, reported that in 2022-23, there were 201 hospital admissions due to sunburn, including 89 children and 25 infants under one year old. Additionally, 66% of UK adults aged 16-65 recalled experiencing sunburn as children, while 65% had suffered severe sunburn with blistering at least once, a figure that rose to 77% for individuals with fair skin. Consequently, the growing number of severe sunburn cases is driving the advanced melanoma market forward.

Leading companies in the advanced melanoma market are prioritizing the development of innovative treatments, such as personalized vaccines, to enhance treatment efficacy, address resistance mechanisms, and offer tailored therapies that improve patient outcomes and survival rates. A personalized vaccine for advanced melanoma is designed for individual patients based on the unique genetic mutations in their tumors. For instance, in April 2023, Merck & Co. Inc., a US-based pharmaceutical company, and Moderna Inc., a US-based biotechnology company, received Priority Medicines (PRIME) scheme designation from the European Medicines Agency (EMA) for their investigational personalized mRNA cancer vaccine, mRNA-4157/V940. This vaccine, when combined with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), is intended for the adjuvant treatment of high-risk stage III/IV melanoma patients following complete tumor resection. The mRNA-4157/V940 vaccine contains a single synthetic mRNA encoding up to 34 neoantigens and is custom-designed based on each patient's unique tumor mutation profile.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for $43 billion. This acquisition doubled Pfizer's oncology pipeline, expanding it to 60 programs across various treatment modalities. By integrating Seagen's antibody-drug conjugate (ADC) technology, Pfizer aims to leverage its expertise in protein engineering and medicinal chemistry to develop novel therapeutic combinations and next-generation biologics. Seagen Inc., a US-based biotechnology company, specializes in researching and developing treatments for advanced melanoma, with a strong focus on ADC technology.

Major players in the advanced melanoma market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb, AstraZeneca AG, Novartis AG, GlaxoSmithKline Plc, Amgen Inc., BioNTech SE, Regeneron Pharmaceuticals, Genentech Inc., Exelixis Inc., Dynavax Technologies, Replimune Group, Immunocore Holdings plc, Xencor Inc., Agenus Inc., Nektar Therapeutics, Iovance Biotherapeutics, Adaptimmune Therapeutics, Immutep Ltd., Lytix Biopharma.

North America was the largest region in the advanced melanoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in advanced melanoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the advanced melanoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The advanced melanoma market consists of revenues earned by entities by providing services such as diagnosis and staging, surgical excision, immunotherapy administration, targeted therapy management, palliative care and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The advanced melanoma market also includes sales of pembrolizumab, vemurafenib, trametinib, and personalized cancer vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Advanced Melanoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on advanced melanoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for advanced melanoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The advanced melanoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Therapeutics: Chemotherapy; Biological Therapy; Targeted Therapy; Immune Therapy
• 2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
• 3) By End-User: Hospitals; Cancer Research Centres; Academic Institutes; Diagnostic Centers; Ambulatory Surgical Centers; Other End Users
• Subsegments:
• 1) By Chemotherapy: Alkylating Agents; Antimetabolites; Topoisomerase Inhibitors; Other Chemotherapy Drugs
• 2) By Biological Therapy: Monoclonal Antibodies; Interferons; Interleukins
• 3) By Targeted Therapy: BRAF Inhibitors; MEK Inhibitors; KIT Inhibitors; Other Targeted Therapies
• 4) By Immune Therapy: Immune Checkpoint Inhibitors; Cancer Vaccines; Oncolytic Virus Therapy; Adoptive Cell Transfer
• Companies Mentioned: Pfizer Inc.; F Hoffmann-La Roche Ltd; Merck & Co. Inc.; Bristol-Myers Squibb; AstraZeneca AG; Novartis AG; GlaxoSmithKline Plc; Amgen Inc.; BioNTech SE; Regeneron Pharmaceuticals; Genentech Inc.; Exelixis Inc.; Dynavax Technologies; Replimune Group; Immunocore Holdings plc; Xencor Inc.; Agenus Inc.; Nektar Therapeutics; Iovance Biotherapeutics; Adaptimmune Therapeutics; Immutep Ltd.; Lytix Biopharma
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.